FDA Approval - MarketMinute

Zevra Therapeutics

Zevra Therapeutics' Stock Soars on Strong Performance and Strategic Wins: What It Means for Investors

Zevra Therapeutics (NASDAQ: ZVRA) has captured significant attention in the financial markets with its recent robust stock performance and a compelling "Strong" Relative Strength Rating. As of early October 2025, the biopharmaceutical company, focused on rare diseases, is demonstrating a positive trajectory, fueled by critical regulatory milestones, impressive

FDA Approval

FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca (lurbinectedin) and Roche's (SIX: ROG, OTCQX: RHHBY) Tecentriq (atezolizumab), along with its subcutaneous formulation Tecentriq Hybreza. This

Merus N.V.

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by Danish biotech giant Genmab A/S (NASDAQ: GMAB). The all-cash transaction, valued at approximately $8.0

Tilray Brands

Tilray Brands Plunges Amidst Mounting FDA Approval Concerns and Regulatory Headwinds

New York, NY – September 25, 2025 – Tilray Brands Inc. (NASDAQ: TLRY) saw its stock tumble by a significant -5.21% on Thursday, September 25, 2025, as investor confidence continued to erode under the weight of persistent FDA approval uncertainties and a challenging regulatory landscape. This latest decline signals growing apprehension

Johnson & Johnson

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet medical needs. From a groundbreaking FDA approval for bladder cancer to promising Phase 3 results for a next-generation psoriasis treatment and

Intel

Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism

In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered significant boosts to investor confidence, signaling robust performance and strategic advancements across diverse sectors. These developments, ranging from substantial investments and strong earnings reports to groundbreaking drug